These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32912193)

  • 1. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development.
    Davis JS; Kanikarla-Marie P; Gagea M; Yu PL; Fang D; Sebastian M; Yang P; Hawk E; Dashwood R; Lichtenberger LM; Menter D; Kopetz S
    BMC Cancer; 2020 Sep; 20(1):871. PubMed ID: 32912193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC.
    Faux MC; Weinstock J; Gogos S; Prato E; Azimpour AI; O'Keefe R; Cathcart-King Y; Garnham AL; Ernst M; Preaudet A; Christie M; Putoczki TL; Buchert M; Burgess AW
    Cancer Res Commun; 2022 Feb; 2(2):66-77. PubMed ID: 36860494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
    Orner GA; Dashwood WM; Blum CA; Díaz GD; Li Q; Al-Fageeh M; Tebbutt N; Heath JK; Ernst M; Dashwood RH
    Mutat Res; 2002 Sep; 506-507():121-7. PubMed ID: 12351151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.
    Itano O; Yang K; Fan K; Kurihara N; Shinozaki H; Abe S; Jin B; Gravaghi C; Edelmann W; Augenlicht L; Kopelovich L; Kucherlapati R; Lamprecht S; Lipkin M
    Carcinogenesis; 2009 Nov; 30(11):1923-6. PubMed ID: 19755659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
    Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp.
    Matsuhashi N; Nakajima A; Shinohara K; Oka T; Yazaki Y
    Am J Gastroenterol; 1998 Nov; 93(11):2261-6. PubMed ID: 9820411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.
    Boon EM; Keller JJ; Wormhoudt TA; Giardiello FM; Offerhaus GJ; van der Neut R; Pals ST
    Br J Cancer; 2004 Jan; 90(1):224-9. PubMed ID: 14710233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
    Alberts DS; Hixson L; Ahnen D; Bogert C; Einspahr J; Paranka N; Brendel K; Gross PH; Pamukcu R; Burt RW
    J Cell Biochem Suppl; 1995; 22():18-23. PubMed ID: 8538196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
    Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
    Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
    Huls G; Koornstra JJ; Kleibeuker JH
    Lancet; 2003 Jul; 362(9379):230-2. PubMed ID: 12885487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer.
    Luk GD
    Schweiz Med Wochenschr; 1996 May; 126(19):801-12. PubMed ID: 8693304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis.
    Qiu W; Wang X; Leibowitz B; Liu H; Barker N; Okada H; Oue N; Yasui W; Clevers H; Schoen RE; Yu J; Zhang L
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20027-32. PubMed ID: 21041628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
    Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
    Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of colorectal cancer: two steps forward, one step back?
    Half EE; Arber N
    Future Oncol; 2006 Dec; 2(6):697-704. PubMed ID: 17155896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.